CEO Monthly Issue 6 2018

10 CEO MONTHLY / ISSUE 6 2018 , Mundipharma is a network of privately owned, independent associated companies that operate in pharmaceutical markets across Asia-Pacific, Latin America, theMiddle East and Africa, headquartered fromSingapore. We spoke to CEO, Raman Singh as we looked to gain an insight into the extensive success that he has overseen throughout his career. A Visionary in the Field of Pharmaceuticals Mundipharma is a network of privately owned, independent associated companies that operate across Asia-Pacific, Latin America, the Middle East and Africa, regionally based in Singapore. Since 2011, we’ve expanded our operations from six countries to more than 120, grown our team from approximately 350 to over 5,000 today, and achieved 24 consecutive quarters of growth. Mundipharma is focused on business transformation by leveraging global leadership in pain and, through a shared spirit of innovation, building a growing presence in antisepsis, respiratory, oncology, ophthalmology, consumer healthcare and other specialty areas. In addition to leading Mundipharma’s operations across Asia-Pacific, Latin America, the Middle East and Africa, I have global responsibility for the organisation’s global consumer healthcare business, including North America and Europe. Important aspects of my role include the development and empowerment of our people at all levels across the organization. At the same time, we continue to place patients at the heart in everything we do and ensuring healthcare professionals and consumers have access to our portfolio of medicines and treatments supports. To me, leadership is about never giving up, no matter how insurmountable a problem might seem. I strive to motivate the people at Mundipharma to do the same; to think differently and to understand the higher calling we have to make a positive impact in the lives of patients. Mundipharma has worked tirelessly to address unmet needs so that the entire human race can enjoy a better quality of life. Because medicines should be for those who need it. Prior to joining Mundipharma I served as vice-president of commercial operations for emerging markets at GSK. In this role, I oversaw all aspects of the brand’s commercial operations across its emerging markets. I’ve previously held positions at Abbott as the regional director in Australia and New Zealand, and general manager for Korea, as well as various sales, marketing and strategy positions at Bayer. I graduated with a Bachelors in Mechanical Engineering. I also hold a Masters of Business Administration from Assumption University and a MBA in International Management from Thunderbird School of International Management. I’m currently a Brand Ambassador for the Singapore Tourism Board, and a Governor of the World Economic Forum Global Health and Healthcare Committee and a part of the Advisory Board at Manchester City Football Club. Three key principles our people embody are innovative flair, an entrepreneurial spirit and a patient-centric ethos. For us, the future for medicines and treatments are developed to be faster and quicker to fulfil the needs for patients. Digitization has helped us tremendously. Today there’s a huge amount of modelling that can predict how a medicine will behave when 1805CE04 it goes to human trial, which can eliminate a lot of cost and time and result in more targeted therapies. However, I strongly believe that the industry needs to adapt further. The future will rely on artificial intelligence, machine learning and virtual reality, in different scopes. In medical research, it will reduce a lot of cost and help develop precision medicine. It will also improve access to medication and consultation to as many people as possible, because infrastructure is a huge limitation: there are not enough hospitals, healthcare providers, the roads are not in place to reach the far out places in the emerging world. Digitization is breaking down a lot of barriers. Some companies are underestimating the impact of digitisation, others, such as Mundipharma, are well on their way. For example, smartphones and apps will enable us to affect a massive infrastructure leap in many parts of the world and transform the quality of healthcare delivery and patient outcomes – we are making progress with applications such